| 2021 |
Raborn LN, Pan KS, FitzGibbon EJ, Collins MT, Boyce AM. Optic disc edema in fibrous dysplasia/McCune-Albright syndrome: prevalence, etiologies, and clinical implications. Bone. February 2021;143:115661. |
0 |
0 |
| 2022 |
Hopkins C, de Castro LF, Corsi A, Boyce A, Collins MT, Riminucci M, Heegaard A-M. Fibrous dysplasia animal models: a systematic review. Bone. February 2022;155:116270. |
0 |
0 |
| 2020 |
Pan KS, de Castro LF, Roszko KL, Greenberg ED, FitzGibbon EJ, Dufresne CR, Boyce AM, Collins MT. Successful intravascular treatment of an intraosseous arteriovenous fistula in fibrous dysplasia. Calcif Tiss Int. August 2020;107(2):195-200. |
0 |
0 |
| 2021 |
Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor-induced osteomalacia. Calcif Tiss Int. January 2021;108(1):128-142. |
3 |
2 |
| 2020 |
Pan KS, FitzGibbon EJ, Vitale S, Lee JS, Collins MT, Boyce AM. Utility of optical coherence tomography in the diagnosis and management of optic neuropathy in patients with fibrous dysplasia. J Bone Miner Res. November 2020;35(11):2199-2210. |
0 |
0 |
| 2021 |
Roszko KL, Brown S, Pang Y, Huynh T, Zhuang Z, Pacak K, Collins MT. C‐terminal, but not intact, FGF23 and EPO are strongly correlatively elevated in patients with gain‐of‐function mutations in HIF2A: clinical evidence for EPO regulating FGF23. J Bone Miner Res. February 2021;36(2):315-321. |
2 |
1 |
| 2022 |
Roszko KL, Hu TY, Guthrie LC, Brillante BA, Smith M, Collins MT, Gafni RI. PTH 1-34 replacement therapy has minimal effect on quality of life in patients with hypoparathyroidism. J Bone Miner Res. January 2022;37(1):68-77. |
1 |
0 |
| 2022 |
Ovejero D, Hartley IR, Diaz LFdC, Theng E, Li X, Gafni RI, Collins MT. PTH and FGF23 exert interdependent effects on renal phosphate handling: evidence from patients with hypoparathyroidism and hyperphosphatemic familial tumoral calcinosis treated with synthetic human PTH 1–34. J Bone Miner Res. February 2022;37(2):179-184. |
1 |
0 |
| 2022 |
Gafni RI, Langman CB, Guthrie LC, Brillante BA, James R, Yovetich NA, Boyce AM, Collins MT. Hypocitraturia is an untoward side effect of synthetic human parathyroid hormone (hPTH) 1–34 therapy in hypoparathyroidism that may increase renal morbidity. J Bone Miner Res. April 2022;37(4):818. |
0 |
0 |
| 2022 |
Roszko KL, Smith LMS, Sridhar AV, Roberts MS, Hartley IR, Gafni RI, Collins MT, Fox JC, Nemeth EF. Autosomal dominant hypocalcemia type 1: a systematic review. J Bone Miner Res. October 2022;37(10):1926-1935. |
0 |
0 |
| 2022 |
Hartley IR, Gafni RI, Roszko KL, Brown SM, de Castro LF, Saikali A, Ferreira CR, Gahl WA, Pacak K, Blau JE, Boyce AM, Salusky IB, Collins MT, Florenzano P. Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia. J Bone Miner Res. November 2022;37(11):2174-2185. |
0 |
0 |
| 2022 |
Van Uum S, Shrayyef M, M'Hiri I, Dandurand K, Ali DS, Bilezikian JP, Collins MT, Mannstadt M, Rubin MR, Siggelkow H, Tabacco G, Tay Y-KD, Vokes T, Winer KK, Yao L, Guyatt G, Rejnmark L, Khan AA. Initial assessment and monitoring of patients with chronic hypoparathyroidism: a systematic current practice survey. J Bone Miner Res. December 2022;37(12):2630-2641. |
4 |
0 |
| 2022 |
Khan AA, Guyatt G, Ali DS, Bilezikian JP, Collins MT, Dandurand K, Mannstadt M, Murphy D, M'Hiri I, Rubin MR, Sanders R, Shrayyef M, Siggelkow H, Tabacco G, Tay Y-KD, Van Uum S, Vokes T, Winer KK, Yao L, Rejnmark L. Management of hypoparathyroidism. J Bone Miner Res. December 2022;37(12):2663-2677. |
5 |
0 |
| 2023 |
Roszko KL, Guthrie L, Li X, Collins MT, de Castro LF, Boyce AM. Identification of GNAS variants in circulating cell-free DNA from patients with fibrous dysplasia/McCune Albright syndrome. J Bone Miner Res. March 2023;38(3):443-450. |
0 |
0 |
| 2023 |
Meier ME, Appelman-Dijkstra NM, Collins MT, Geels RES, Stanton RP, de Witte PB, Boyce AM, van de Sande MAJ. Coxa vara deformity in fibrous dysplasia/McCune-Albright syndrome: prevalence, natural history and risk factors: a two-center study. J Bone Miner Res. July 2023;38(7):968-975. |
0 |
0 |